Filing Details
- Accession Number:
- 0001213900-24-035720
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2024-04-24 14:07:17
- Reporting Period:
- 2024-04-19
- Accepted Time:
- 2024-04-24 14:07:17
- Original Submission Date:
- 2024-04-23
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1711754 | Inmune Bio Inc. | INMB | Biological Products, (No Disgnostic Substances) (2836) | 475205835 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1767084 | Scott Juda | C/O Inmune Bio Inc. 225 Ne Mizner Blvd., Suite 640 Boca Raton FL 33432 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-04-19 | 29,603 | $8.32 | 66,603 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Common Stock Warrants (right to buy) | Acquisiton | 2024-04-19 | 29,603 | $0.13 | 29,603 | $9.15 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 29,603 | 2024-04-24 | No | 4 | P | Direct |
Footnotes
- The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $249,997.34 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant.
Billionaire Hedge Funds
